URO Antibodies

Santa Cruz Biotechnology delivers a wide array of URO monoclonal antibodies for studying urokinase-type plasminogen activator (uPA) and its receptor (uPAR). URO monoclonal antibodies are validated for multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Urokinase-type plasminogen activator plays a critical role in the regulation of fibrinolysis and tissue remodeling, influencing processes such as cell migration, invasion, and angiogenesis. The interaction between uPA and uPAR is essential for various physiological and pathological conditions, including cancer progression and wound healing. Understanding the function of uPA and uPAR is crucial for developing therapeutic strategies targeting specific pathways. Research utilizing URO monoclonal antibodies has revealed significant insights into cellular signaling mechanisms and potential therapeutic targets. Investigating uPA and uPAR expression patterns helps identify biomarkers for disease progression and treatment response. URO monoclonal antibodies enable researchers to explore complex biological processes and contribute to advancing scientific knowledge in cancer research and regenerative medicine. Santa Cruz Biotechnology monoclonal antibodies support the scientific community by facilitating breakthrough discoveries in uPA and uPAR research.